Protagonist Obtains Third Patent for Therapy Targeting a Bowel Disease-related Protein

Protagonist Obtains Third Patent for Therapy Targeting a Bowel Disease-related Protein
Protagonist Therapeutics has obtained a U.S. patent for an inflammatory bowel disease treatment that is in clinical trials. PTG-100 inhibits a protein known as alpha-4-beta-7 integrin that is associated with IBDs. Scientists consider it one of the most important targets for therapies to alleviate the conditions. The patent is the third Protagonist has obtained for the inhibitors. The others can

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *